GTS Securities’s AstraZeneca AZN Stock Holding History

GTS Securities’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-19,150	Closed	-$2.98M	–	1495
2024 Q3	$2.98M	Sell	19,150 -2,000	-9%	-$323K	0.01%	1276
2024 Q2	$3.3M	Sell	21,150 -21,650	-51%	-$3.26M	0.01%	1132
2024 Q1	$5.8M	Buy	42,800 +20,150	+89%	+$2.67M	0.01%	761
2023 Q4	$3.05M	Sell	22,650 -20,450	-47%	-$2.66M	0.01%	1340
2023 Q3	$5.84M	Buy	+43,100	New	+$5.89M	0.01%	849

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GTS Securities's AZN Position: Q2 2026 in Review

GTS Securities sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 6,500 shares — an estimated $1.28M sold.

GTS Securities first reported a position in AZN in Q3 2023 and held it in 10 quarters. The position peaked at $4.74M in Q2 2025. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

GTS Securities reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
GTS Securities sold 6,500 AstraZeneca shares in Q2 2026, an estimated $1.28M.
GTS Securities first reported a position in AstraZeneca in Q3 2023 and held it in 10 quarters.
GTS Securities's AstraZeneca position peaked at $4.74M in Q2 2025.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.